Novo Nordisk A/s

Thomas Egebjerg

Jais Rose Bjelke

Per J Greisen

Philip Jonas Sassene

Marie-Ange Buyse

Jens Breinholt

Lars Christian Petersen

Soren Steffensen

Frantisek Hubalek

Ida Hilden

Steffen Reedtz-Runge

Jes Thorn Clausen

Anette Henriksen

Susanne Nedergaard Grell

Mathias Norrman

Mette Dahl Andersen

Andreas Vegge

Evelyn De Tavernier

Jacob Lund

Thomas Nylandsted Krogh

Daniele Granata

Simone Fulle

Emma Balantic-Nielsen

Che Yang

Katharina Luise Maria Kopp

The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).

Anti IL-6 domain antibodies with fatty acid substituents

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.

Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration

The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.

Targeting tissue factor to activated platelets

Growing community of inventors

Ganloese, Denmark

Thomas Egebjerg